Nuformix (LON:NFX) Stock Falls 12% – Should You Sell?
by Mitch Edgeman · The Markets DailyNuformix plc (LON:NFX – Get Free Report)’s share price fell 12% during mid-day trading on Wednesday. The stock traded as low as GBX 0.11 and last traded at GBX 0.11. Approximately 24,017,961 shares changed hands during trading, a decline of 17% from the average session volume of 29,027,189 shares. The stock had previously closed at GBX 0.12.
Nuformix Trading Down 12.0%
The company has a market capitalization of £2.87 million, a PE ratio of -3.75 and a beta of 1.53. The business’s 50-day simple moving average is GBX 0.15 and its two-hundred day simple moving average is GBX 0.17.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.